KRAS and neoplasm: This study provides a compelling proof-of-concept for the <i>in vitro</i> delivery of KRAS<sup>G12C</sup> mutant-specific inhibitors and degraders to human tumors through a tumor microenvironment-activated nanomedicine approach and lays the groundwork for future studies in physiologically relevant models to assess TME-specific activation and tumor selectivity.